Pharmaceutical interventions in smoking cessation: systematic review protocol




Pharmaceutical Services; Smoking Cessation; Tobacco Use Disorder; Protocol.


Objective: To describe the methodological steps to carry out a systematic review of pharmaceutical interventions for smoking cessation. Review Method: The protocol for this Systematic Review was developed according to the recommendations of the Prism P guidelines. Will be used as exclusion criteria: comments, editorials, articles that were not in Portuguese, Spanish, and English or articles that were not available in full. Also, articles indexed repeatedly in two or more databases will only be considered once. Two independent reviewers will evaluate titles, abstracts and full texts. Differences in selection will be resolved through a third reviewer. Discussion: This review will aim to critically synthesize the clinical evidence surrounding pharmaceutical interventions for smoking cessation, including data on ethnicity, age, socioeconomic conditions, level of health care, and the intervention environment. Therefore, the use of validated procedures and instruments to assess pharmaceutical interventions in support of smoking patients is essential. Conclusion: This protocol aims to describe the methodological steps to carry out a systematic review of pharmaceutical interventions for smoking cessation, aiming to reduce biases in the search and selection of references, making these criteria clear and uniform among reviewers.


Brozek, J. L., Akl, E. A., Alonso-Coello, P., Lang, D., Jaeschke, R., Williams, J. W., Phillips, B., Lelgemann, M., Lethaby, A., Bousquet, J., Guyatt, G. H., Schünemann, H. J., & GRADE Working Group (2009). Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy, 64(5), 669–677.

Carson-Chahhoud, K. V., Livingstone-Banks, J., Sharrad, K. J., Kopsaftis, Z., Brinn, M. P., To-A-Nan, R., & Bond, C. M. (2019). Community pharmacy personnel interventions for smoking cessation. The Cochrane database of systematic reviews, 2019(10), CD003698.

CTAG, (2017). The Cochrane Tobacco Addiction Group twentieth anniversary priority setting project (CTAG taps) final report. 2017. Oxford, UK: Cochrane Tobacco Addiction Group. [

Dent, L. A., Harris, K. J., & Noonan, C. W. (2007). Tobacco interventions delivered by pharmacists: a summary and systematic review. Pharmacotherapy, 27(7), 1040–1051.

Francisco, P. M. S. B., Assumpção, D. de, Borim, F. S. A., Senicato, C., & Malta, D. C. (2019). Prevalence and co-occurrence of modifiable risk factors in adults and older people. Revista De Saúde Pública, 53, 86.

Global Burden of Disease [database]. Washington, DC: Institute of Health Metrics, IHME;(2019).

Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., Schünemann, H. J., & GRADE Working Group (2008). GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ (Clinical research ed.), 336(7650), 924–926.

Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A., Cochrane Bias Methods Group, & Cochrane Statistical Methods Group (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed.), 343, d5928.

Kelling SE (2015). Exploring Accessibility of Community Pharmacy Services.Inov Pharm. Innovations in Pharmacy; 6(3): Article 210.

Lee, J. J., Wang, M. P., & Yang, S. C. (2021). Will the tobacco industry ultimately triumph in the midst of COVID-19 pandemic?: A call for nurses' action in tobacco control. International journal of nursing studies, 115, 103726.

Lopez, A., & Mathers, C. (2006). Measuring the global burden of disease and epidemiological transitions: 2002–2030. Annals of Tropical Medicine & Parasitology, 100, 481 - 499.

McHugh M. L. (2012). Interrater reliability: the kappa statistic. Biochemia medica, 22(3), 276–282.

Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & PRISMA-P Group (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews, 4(1), 1.

Ouzzani M., Hammady H., Fedorowicz Z., Elmagarmid A. (2016). Rayyan-a Web and mobile App for Systematic Reviews. Syst. Rev. 5 (1), 210. 10.1186/s13643-016-0384-4

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., McGuinness, L. A., … Moher, D. (2021). The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed.), 372, n71.

Saba, M., Diep, J., Saini, B., & Dhippayom, T. (2014). Meta-analysis of the effectiveness of smoking cessation interventions in community pharmacy. Journal of clinical pharmacy and therapeutics, 39(3), 240–247.


WORLD HEALTH ORGANIZATION. Global status report on noncommunicable diseases 2010. Description of the global burden of NCDs, their risk factors and determinants. Geneva: World Health Organization; 2011.

WORLD HEALTH ORGANIZATION. Report on the global tobacco epidemic, 2017: monitoring tobacco use and prevention policies. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO.




How to Cite

ALMEIDA, D. S. S. F. de; ALMEIDA, F. H. O. de; CRISTINO, I. de S. .; SOUZA, C. A. S.; SILVA, F. A. da. Pharmaceutical interventions in smoking cessation: systematic review protocol. Research, Society and Development, [S. l.], v. 10, n. 12, p. e52101220170, 2021. DOI: 10.33448/rsd-v10i12.20170. Disponível em: Acesso em: 21 feb. 2024.



Health Sciences